Nutex Health, Inc. (NUTX) AI Stock Analysis

Nutex Health Inc. operates a network specializing in micro-hospitals through two primary segments: Healthcare and Real Estate. The Healthcare segment encompasses corporate-level entities, emergency rooms, and Professional Limited Liability Companies, offering emergency care, inpatient services, behavioral health, certified laboratories, inpatient pharmacies, and diagnostic imaging such as CT scans, X-rays, MRIs, and ultrasounds. The Real Estate segment leases land and hospital buildings to support its physical footprint. Additionally, the company provides integrated healthcare management services, including billing, coding, and collection solutions. Nutex Health owns and manages 21 facilities across 8 states in the United States.

Nutex Health delivered a 5-year revenue compound annual growth rate of 26.1% from FY2020 to FY2025. Annual revenue expanded from $331.5M in FY2021 to $875.3M in FY2025, rebounding from a decline to $219.3M in FY2022. Operating margin recovered from -185.4% in FY2022 and -12.8% in FY2023 to 27.2% in FY2024 and 31.5% in FY2025. Over the same period, net income shifted from a net loss of -$424.8M in FY2022 to a profit of $70.8M in FY2025, yielding diluted earnings per share of $16.39. In the latest quarter ended June 30, 2026, quarterly revenue fell 13.6% year-over-year, while quarterly earnings grew 95.9%.

As of June 30, 2026, Nutex Health held $205.2M in cash and short-term investments against total debt of $347.3M, resulting in net debt of $142.1M. Shareholders' equity was $394.3M, with total assets of $964.6M, a current ratio of 5.00, and a debt-to-equity ratio of 0.88. In FY2025, operating cash flow reached $248.1M and free cash flow was $245.6M. Capital expenditures were $2.5M, while share buybacks totaled $5.0M and dividends paid equaled $74.3M.

Nutex Health carries a market capitalization of $1.27B and an enterprise value of $852.1M. The stock trades at a trailing price-to-earnings ratio of 7.4x, below the 24.6x median of its US-listed Healthcare peers. Its price-to-sales ratio of 1.5x is lower than the peer median of 4.1x, while its enterprise value-to-EBITDA ratio stands at 90.0x compared to the peer median of 12.0x. Over the past year, shares returned 92.5%, outpacing the S&P 500 (SPY) return of 16.8%, though the five-year return was -73.3% versus 83.0% for SPY.

Wall Street coverage consists of 4 Strong Buy ratings and 1 Buy rating, with zero Hold, Sell, or Strong Sell ratings. The mean price target is $288.20, representing an upside of 54.9% from the last close of $186.10. For the current fiscal year ending December 31, 2026, analysts estimate revenue of $872.0M and earnings per share of $27.79. Over the last four quarters, Nutex Health beat earnings estimates 3 times. The company's next earnings date is November 18, 2026.

This page is an AI-written research summary of Nutex Health, Inc. (NUTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NUTX income statement, NUTX balance sheet, NUTX key metrics, NUTX analyst forecast, NUTX chart. See the NUTX stock overview for the latest quote and news.